A novel MDMA-like chemical series have been identified with drug-like properties which will be developed to treat addiction.
New data has shown that Amanita Muscaria extract (AME-1) has a potential new functional property – inhibiting human mast cell activation – which could hold promise...
A clinical trial investigating the safety and tolerability of a novel formulation of 5-MeO-DMT in psychedelic-naive subjects has dosed its first cohort of volunteers.
With limited treatment options available for the condition, one company is setting out to explore the neurogenic potential of psychedelics to combat the cognitive decline of...
Currently, there is no cure for Parkinson’s Disease, however, certain medications can help improve symtoms.
Real-time quantification of brain activity during the psychedelic experience has been a major barrier within psychedelic research.
Results from a recent study have demonstrated a significant reduction in depressive symptoms and suicidality using ketamine as a solo treatment.
Data from Lobe Sciences has demonstrated that combination therapy of psilocybin and N-Acetylcysteine is more effective than monotherapy for mTBI and PTSD.
Better Life Pharma has obtained its first set of data on its lead compound TD-0148A, a second-generation LSD derivative, with further preclinical studies underway to determine...
Delix Therapeutics has raised $70m in a Series A funding round which is expected to fund its drug discovery platform of novel neuroplasticity-promoting compounds known as...